| 1. |
Wang J, Zheng Q, Chen J. Immune checkpoint inhibitor-induced autoimmune encephalitis in metastatic squamous cell lung cancer. Immunotherapy, 2023, 15(6): 409-416.
|
| 2. |
Farina A, Villagrán-García M, Vogrig A, et al. Central nervous system adverse events of immune checkpoint inhibitors. Curr Opin Neurol, 2024, 37(3): 345-352.
|
| 3. |
Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer, 2021, 9(6): e002435.
|
| 4. |
Marini A, Bernardini A, Gigli GL, et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology, 2021, 96(16): 754-766.
|
| 5. |
Fonseca E, Cabrera-Maqueda JM, Ruiz-García R, et al. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study. Lancet Neurol, 2023, 22(12): 1150-1159.
|
| 6. |
Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol, 2023, 14: 1167975.
|
| 7. |
Farina A, Villagrán-García M, Joubert B. Soluble biomarkers for immune checkpoint inhibitor-related encephalitis: A mini-review. Rev Neurol (Paris), 2024, 180(9): 982-988.
|
| 8. |
Farina A, Birzu C, Elsensohn MH, et al. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun, 2023, 5(3): fcad169.
|
| 9. |
Taliansky A, Furman O, Gadot M, et al. Immune checkpoint inhibitors-related encephalitis in melanoma and non-melanoma cancer patients: a single center experience. Support Care Cancer, 2021, 29(12): 7563-7568.
|
| 10. |
Lopes S, Pabst L, Bahougne T, et al. Central nervous system complications of immune checkpoint inhibitors: A comprehensive review. Crit Rev Oncol Hematol, 2025, 206: 104595.
|
| 11. |
Chisaki Y, Hata H, Matsumura C, et al. The occurrence of encephalitis due to immune checkpoint inhibitors: a pharmacovigilance study. Ther Innov Regul Sci, 2022, 56(2): 323-332.
|
| 12. |
Schagen SB, Tsvetkov AS, Compter A, et al. Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach? Nat Rev Neurol, 2022, 18(3): 173-185.
|
| 13. |
Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol, 2019, 16(9): 535-548.
|
| 14. |
Gill A, Perez MA, Perrone CM, et al. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes. J Neuroimmunol, 2019, 334: 576980.
|
| 15. |
Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med, 2019, 25(8): 1243-1250.
|
| 16. |
Velasco R, Villagrán M, Jové M, et al. Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol, 2021, 78(7): 864-873.
|
| 17. |
Müller-Jensen L, Zierold S, Versluis JM, et al. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study. Eur J Cancer, 2022, 175: 224-235.
|
| 18. |
Farina A, Villagrán-García M, Fourier A, et al. Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study. Lancet Reg Health Eur, 2024, 44: 101011.
|
| 19. |
De la Hoz A, Foolad F, Gallegos C, et al. Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin's disease. Bone Marrow Transplant, 2019, 54(5): 749-751.
|
| 20. |
Yonenobu Y, Ishijima M, Toyooka K, et al. A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer. Rinsho Shinkeigaku, 2019, 59(2): 105-108.
|
| 21. |
Vogrig A, Mu?iz-Castrillo S, Joubert B, et al. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry, 2020, 91(7): 772-778.
|
| 22. |
Chung M, Jaffer M, Verma N, et al. Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange. J Neurol, 2020, 267(4): 1023-1025.
|
| 23. |
Erol-Y?ld?z R, K?z?lay T, Tüzün E, et al. Nivolumab-induced autoantibody negativelimbic encephalitis in a patient with Hodgkin lymphoma. Leuk Lymphoma, 2020, 61(6): 1519-1521.
|
| 24. |
Kang K, Zheng K, Zhang Y. Paraneoplastic Encephalitis and enteric neuropathy associated with anti-Hu antibody in a patient following immune-checkpoint inhibitor therapy. J Immunother, 2020, 43(5): 165-168.
|
| 25. |
Taillefer VT, Pigeon M, Chen M, et al. Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: a case report. J Oncol Pharm Pract, 2020, 26(6): 1538-1543.
|
| 26. |
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol, 2021, 39(36): 4073-4126.
|
| 27. |
Couey MA, Bell RB, Patel AA, et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer, 2019, 7(1): 165.
|
| 28. |
Valencia-Sanchez C, Sechi E, Dubey D, et al. Immune checkpoint inhibitor-associated central nervous system autoimmunity. Eur J Neurol, 2023, 30(8): 2418-2429.
|
| 29. |
Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol, 2016, 15(4): 391-404.
|
| 30. |
Dinoto A, Mantovani E, Ferrari S, et al. Cerebellar involvement associated with immune checkpoint inhibitors: a systematic review. Eur J Neurol, 2023, 30(3): 774-781.
|
| 31. |
Gao Y, Pan J, Shen D, et al. Immune checkpoint inhibitor associated autoimmune encephalitis, rare and novel topic of neuroimmunology: a case report and review of the literature. Brain Sci, 2022, 12(6): 773.
|
| 32. |
Nersesjan V, McWilliam O, Krarup LH, et al. Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review. Neurology, 2021, 97(2): e191-e202.
|
| 33. |
Quirynen R, Ocak S, Duplaquet F, et al. Long-term complete remission after severe pembrolizumab-induced immune-related encephalitis in metastatic lung adeno-squamous carcinoma: a case report. Respir Med Case Rep, 2023, 45: 101898.
|
| 34. |
Sechi E, Markovic SN, McKeon A, et al. Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes. Neurology, 2020, 95(17): e2442-e2452.
|
| 35. |
Farina A, Villagrán-García M, Ciano-Petersen NL, et al. Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm, 2022, 10(1): e200058.
|
| 36. |
Vogrig A, Fouret M, Joubert B, et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm, 2019, 6(6): e604.
|
| 37. |
Graus F, Vogrig A, Mu?iz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm, 2021, 8(4): e1014.
|
| 38. |
Cohen J, Sotoca J, Gandhi S, et al. Autoimmune encephalitis: A costly condition. Neurology, 2019, 92(9): e964-e972.
|
| 39. |
Bjursten S, Zhao Z, Al Remawi H, et al. Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor-induced CNS inflammation. EBioMedicine, 2024, 100: 104955.
|
| 40. |
Farina A, Villagrán-García M, Benaiteau M, et al. Opsoclonus-ataxia syndrome in a patient with small-cell lung cancer treated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm, 2024, 11(5): e200287.
|
| 41. |
Bjursten S, Pandita A, Zhao Z, et al. Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis. J Immunother Cancer, 2021, 9(7): e002732.
|
| 42. |
Shi J, Niu J, Shen D, et al. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system. Thorac Cancer, 2020, 11(2): 481-487.
|
| 43. |
Guidon AC, Burton LB, Chwalisz BK, et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer, 2021, 9(7): e002890.
|
| 44. |
Wang YY, Song JJ. A case report of the diagnosis and treatment of immune checkpoint inhibitor-related encephalitis induced by camrelizumab. AME Case Rep, 2024, 8: 101.
|
| 45. |
Muley SA, Jacobsen B, Parry G, et al. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve, 2020, 61(5): 575-579.
|
| 46. |
Chauvet E, Blanchard Rohner G, Manel V, et al. Autoantibodies to a nodal isoform of neurofascin in pediatric chronic inflammatory demyelinating polyneuropathy. Child Neurol Open, 2023, 10: 2329048X221149618.
|
| 47. |
Liu X, Wu W, Fang L, et al. TNF-α inhibitors and other biologic agents for the treatment of immune checkpoint inhibitor-induced myocarditis. Front Immunol, 2022, 13: 922782.
|
| 48. |
Hottinger AF, de Micheli R, Guido V, et al. Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis. Neurol Neuroimmunol Neuroinflamm, 2018, 5(2): e439.
|
| 49. |
Thummalapalli R, Sena LA, Probasco JC, et al. Checkpoint inhibitor-induced autoimmune encephalitis reversed by rituximab after allogeneic bone marrow transplant in a patient with Hodgkin lymphoma. Leuk Lymphoma, 2020, 61(1): 228-230.
|
| 50. |
Shin YW, Lee ST, Park KI, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord, 2017, 11: 1756285617722347.
|
| 51. |
Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther, 2021, 6(1): 402.
|
| 52. |
Ciano-Petersen NL, Mu?iz-Castrillo S, Birzu C, et al. Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis. Brain Commun, 2022, 4(4): fcac196.
|
| 53. |
Esfahani K, Elkrief A, Calabrese C, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol, 2020, 17(8): 504-515.
|
| 54. |
Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res, 2018, 6(9): 1093-1099.
|
| 55. |
Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol, 2019, 5(9): 1310-1317.
|
| 56. |
Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin, 2020, 70(2): 86-104.
|
1/5
WeChat